Noxopharm (ASX:NOX) share price jumps 13% on COVID treatment update

This drug development company's shares are racing higher today…

| More on:
elderly woman cheers in doctor's office

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Noxopharm Ltd (ASX: NOX) share price has been a strong performer on Monday.

The clinical-stage drug development company's shares were up as much as 13% to 63 cents at one stage today.

The Noxopharm share price has since pulled back and is now trading just 3.5% higher at 57.5 cents.

Why is the Noxopharm share price rocketing higher?

The Noxopharm share price was given a big boost this morning from the release of a positive announcement.

That announcement reveals that the company is positioning its Veyonda (idronoxil) product as a COVID-19 treatment. This is based on a well-tolerated and selective anti-inflammatory action.

According to the release, this follows an important discovery about the anti-inflammatory mechanism of action of idronoxil through its partnership with Hudson Institute of Medical Research.

The release reveals that the discovery is the identification of the enzyme, TANK-binding kinase 1 (TBK1), as the molecular target of idronoxil in terms of its anti-inflammatory properties.

However, it is worth noting that the discovery is not yet peer reviewed in a scientific publication. A submission is anticipated in two months.

Management commentary

The Hudson Institute's Associate Professor and Head of the Nucleic Acids and Innate Immunity Laboratory, Michael Gantier, said: "TBK1 is a point of convergence of many inflammatory pathways, and a target under significant investigation by several big pharmaceutical companies. Our latest findings, which are being prepared for publication, demonstrate that idronoxil may have applications in a range of diseases where TBK1 facilitates aberrant inflammation."

"Critically, TBK1 also directly controls production of interferon-beta, a cytokine associated with long-COVID symptoms. This suggests that idronoxil may not only be useful to prevent progression of COVID-19 patients from mild to severe disease, but also may decrease the risk of long-lasting post-infectious symptoms, seen in up to half of COVID-19 patients," he added.

The Noxopharm share price is up 22% since the start of the year.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Gainers

Why Cogstate, DroneShield, Premier Investments, and South32 shares are storming higher

These shares are having a strong session on Thursday. But why?

Read more »

three men stand on a winner's podium with medals around their necks with their hands raised in triumph.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another red day on the markets this Wednesday.

Read more »

Multiracial happy young people stacking hands outside - University students hugging in college campus - Youth community concept with guys and girls standing together supporting each other.
Share Gainers

Why 4DMedical and these ASX shares are up 200%+ in just a year

These shares have made their shareholders wealthy over the past year.

Read more »

Three happy office workers cheer as they read about good financial news on a laptop.
Share Gainers

Why Evolution Mining, Lynas Rare Earths, Paladin Energy, and Sovereign Metals shares are racing higher today

These shares are having a good session on hump day. But why?

Read more »

A young well-dressed couple at a luxury resort celebrate successful life choices.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors kept up the selling this session.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rough start to the week for investors.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Share Gainers

Why Catalyst Metals, Lynas, Polynovo, and St George Mining shares are pushing higher today

These shares are starting the week with a bang. But why?

Read more »

A few gold nullets sit on an old-fashioned gold scale, representing ASX gold shares.
Gold

Guess which surging ASX gold share is leaping another 18% today on high-grade results

Investors are piling into this small-cap ASX gold share today. But why?

Read more »